杂志简称：j hepatol
中文译名：《肝脏病学杂志》
收录属性：高质量科技期刊（t1）, scie（2024版）, 目次收录（维普）,英文期刊,
自引率：4.10%
投稿方向：医学、gastroenterology & hepatology 胃肠肝病学
SCI/E期刊基本信息
出版周期：月刊 地区：荷兰
中科院分区：1区
是否TOP：TOP期刊
是否综述：非综述期刊
是否OA：非OA期刊
国际标准刊号：ISSN0168-8278；EISSN1600-0641
杂志语言：英语
出版国家：荷兰
杂志官网 联系方式
出版地址：ELSEVIER SCIENCE BV,PO BOX 211,AMSTERDAM,NETHERLANDS,1000 AE
杂志邮箱：
投稿网址：https://www.editorialmanager.com/jhepat
杂志官方网址：https://www.journals.elsevier.com/journal-of-hepatology
出版商网址：http://www.elsevier.com
杂志投稿要求
投稿须知【杂志社官方网站信息】
Guide for Authors
Statement
Due to the unpredictable clinical duties caused by the COVID-19 pandemic, our editors and reviewers might have difficulties in meeting the deadlines associated with our peer-review process. We remain committed to ensure a timely review of our manuscripts. However, manuscript turnaround times might be longer than usual. We thank our authors for their patience in these difficult times.
The Journal of Hepatology, the official journal of the European Association for the Study of the Liver (EASL), publishes articles describing clinical and basic investigations in the field of hepatology.
Dr Paolo Angeli
Editor-In-Chief
Manuscript submission: https://www.editorialmanager.com/jhepat/default.aspx
Editorial policies
Types of manuscripts
Preparing your manuscript
Disclosures
Research Data
Review process
Submission checklist
Contact the Editorial office
EDITORIAL POLICIES
Ethics in publishing
For information on Ethics in publishing and ethical guidelines for journal publication see https://www.elsevier.com/publishingethics and https://www.elsevier.com/journal-authors/ethics.
Authorship and contributors
As stated in the ICMJE recommendations, credit for authorship requires:
(a) substantial contributions to the conception and design; or the acquisition, analysis, or interpretation of the data,
(b) the drafting of the article or critical revision for important intellectual content,
(c) final approval of the version to be published, and
(d) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. An author contribution statement is required as part of the title page (study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis; obtained funding; administrative, technical, or material support; study supervision).
Changes to authorship
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts. Before the accepted manuscript is published in an online issue, requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager at jhepat@elsevier.com from the corresponding author of the accepted manuscript and must include:
(a) the reason the name should be added or removed, or the order of the authors rearranged; and
(b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement.
In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed. After the accepted manuscript is published in an online issue, any requests to add, delete, or rearrange author names in an article published will follow the same policies as noted above and result in a corrigendum.
Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' which contains forms for copyright assignment, financial disclosures and authorship responsibility. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement. It is the authors' responsibility to make sure these forms are signed and duly returned to the Editorial office via e-mail. If these forms are not received the manuscript will not be published.
Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals. Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see the 'Multiple, redundant or concurrent publication' section of our ethics policy for more information).
Disclosures
Declaration of interest
All authors are required to provide a Declaration of Interest Statement and should complete a standard form, which is available at www.icmje.org/conflicts-of-interest/. This form should be uploaded with the revised manuscript at submission. Further information is available at http://www.icmje.org/recommendations as well. The forms should be uploaded as a single supplementary disclosure file.
All authors are requested to disclose any actual or potential conflict of interest including any financial, activities, additional affiliations, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. See also https://www.elsevier.com/conflictsofinterest. Further information and an example of a conflict of interest form can be found at: https://service.elsevier.com/app/answers/detail/a-id/286/kw/conflict%20of%20interest/p/10523/supporthub/publishing.
Drug declaration
A drug declaration statement/disclosure form will be sent to the corresponding author after acceptance. Authors must select the statement that is most appropriate for their manuscript. This form as well as the copyright forms must be returned to the Editorial office via e-mail.
Submission declaration
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.
Financial disclosure
Authors are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.
Ethics approval
Manuscripts reporting data from research conducted on humans must include a statement of assurance in the methods section of the manuscript reading that: (1) written informed consent was obtained from each patient included in the study and (2) the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.
Clinical trials
The International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org) defines a clinical trial as any research project that prospectively assigns human participants to intervention or comparison groups to study the cause-and-effect relationship between an intervention and a health outcome. Interventions include but are not limited to drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like. Authors of manuscripts reporting clinical trials must submit a proof of institutional review board approval from all participating centers, the original approved protocol, patient information sheet and statistical analysis plan, and all subsequent amendments to either document. All these documents must be in English language. If the manuscript is accepted, the protocol and statistical analysis plan will be published as an online supplement. The trial registration number must be included on the title page of the manuscript reporting a registered clinical trial. Failure to do so will prevent entry to the peer review process.
For randomized control trials, in appropriate places in the manuscript, please provide the following items:
The identity of those who designed the protocol and analyzed the data.
A statement indicating that at least one author had access to all of the data and can vouch for the integrity of the data analyses.
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication.
Statements of role, if any, of medical writer or editor.
Registration of clinical trials
Registration in a public trials registry is a condition for publication of clinical trials in the Journal of Hepatology in accordance with International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org) recommendations. Trials must register at or before the onset of patient enrolment. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.
Acceptable trial registries include the following and others listed at http://www.icmje.org:
http://www.anzctr.org.au
http://www.clinicaltrials.gov
http://isrctn.org
http://www.trialregister.nl/trialreg/index.asp
http://www.umin.ac.jp/ctr
Clinical trial results
In line with the position of the ICMJE, the Journal of Hepatology will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardize consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.
Experimental animal studies
Manuscripts reporting experiments using animals must include a statement giving assurance that all animals received human care and that study protocols comply with the institution's guidelines. Studies involving animal experiments should conform to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (http://www.nc3rs.org.uk/arrive-guidelines), developed by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) to improve standards and reporting of animal research. Please review the ARRIVE checklist and disclose all relevant animal research information as directed.
Where applicable the strain and sex should be reported, if both male and females animals were used then the number of each should be specified. In relation to cell cultures and tissue samples used the sex of the animals used should be specified.
For all manuscripts reporting animal experimentation the authors must state in the methods section:
A statement referring to the above guidelines.
A statement on institutional approval.
Where applicable:
– The strain and sex should be reported, if both male and females animals were used then the number of each should be specified;
– Genetic background of animals used;
– In relation to cell cultures and tissue samples the sex of the animals;
– State the transgenic or genetic mouse model used, and what control mice were used;
– Housing of animals, cage system, enriched environment, diet, food, light or dark cycle.
Mouse strains and cell lines should be italicized and superscript if they are knockout or transgenic strains, e.g., ob/ob (KO), p53+/+, p53-/-.
Statistical methods used should be outlined, in addition to if sex was considered a factor in the statistical analysis.